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Abstract 
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Haemodynamic stress during haemodialysis results in recurrent segmental ischemic 
injury (myocardial stunning) that drives cumulative cardiac damage. We have 
performed the first fully comprehensive study of the cardiovascular impact of dialysis 
sessions using intra-dialytic cardiac magnetic resonance imaging (MRI), applying this 
approach to examine the comparative acute effects of standard haemodialysis (HD) 
versus haemodiafiltration (HDF) in stable patients.  
12 HD patients (32-72 years) were randomly allocated to either HD or HDF. Patients 
were stabilized on a modality for two weeks before undergoing serial cardiac MRI 
assessment during dialysis. Patients then crossed-over to the other modality, and 
were rescanned after a further two weeks. Cardiac MRI measurements included 
cardiac index (CI), stroke volume index (SVI), global and regional contractile function 
(myocardial strain), coronary artery flow and myocardial perfusion. 
Ultrafiltration rate was 3.82.9ml/kg/hr during HD and 4.42.5ml/kg/hr during HDF 
(p=0.29) and both modalities provided a similar degree of cooling. All measures of 
systolic contractile function fell during HD and HDF, with partial recovery post-dialysis. 
All patients experienced some degree of segmental left ventricular dysfunction with 
severity proportional to ultrafiltration rate and blood pressure reduction. Myocardial 
perfusion was significantly reduced during dialysis for HD and HDF. Treatment 
modality did not influence any of the cardiovascular responses to dialysis. 
In conclusion, in this randomized cross-over study, there was no significant difference 
in the cardiovascular response of haemodiafiltration or haemodialysis with cooled 
dialysate as assessed by intradialytic MRI.  
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Introduction 
Cardiac magnetic resonance imaging (MRI) is regarded as the optimal technique for 
structural and functional assessment of the heart but due to the challenging 
environment of an MR scanner, has not previously been used during haemodialysis 
treatment. In addition to superior image quality, MRI is the only imaging modality that 
can provide a complete and simultaneous assessment of cardiac morphology, cardiac 
output, global/regional contractile function, fibrosis, coronary artery flow and 
contrast-free measurement of myocardial perfusion [1]. Haemodynamic instability 
during dialysis plays a central role in the pathophysiology of cardiac disease. A 
substantial body of evidence exists to demonstrate that subclinical myocardial 
ischaemia occurs during conventional HD, driven to a large extent by ultrafiltration 
volume (UFV) and change in blood pressure (BP) [2-5]. The repetitive nature of this 
ischaemic injury has a cumulative effect, leading to permanent reductions in left 
ventricular (LV) systolic function and conferring an increased risk of cardiac events and 
mortality [6]. To date, these findings have largely been generated using 
echocardiography to assess regional myocardial contractility [7, 8], alongside two 
small studies using positron emission tomography (PET) to measure myocardial 
perfusion during HD [9, 10]. On-line haemodiafiltration (HDF) is a modified 
haemodialysis (HD) modality incorporating increased convective clearance, which has 
long been reported to reduce intradialytic hypotension (IDH) [11-14].  However, 
despite three randomised controlled trials and several meta-analyses, opinion 
remains conflicted as to whether HDF improves patient outcomes and the 
mechanisms by which HDF may do so are not well elucidated [11-18]. 
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This study had two principle objectives: to perform the first intradialytic assessment 
of the acute cardiac effects of dialysis using cardiac MRI; secondly to use this method 
to compare the acute cardiac effects of optimized conventional high-flux HD and HDF.  
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Results 
Subjects 
60 established HD patients were screened for eligibility, from whom 12 consented to 
participate (10 male, mean age 53±12years, dialysis vintage 56±6months). All had an 
arterio-venous fistula (AVF) with mean flow rate (Qa) of 1051±60ml/min. Demographic 
data are shown in Table 1.  
 
Dialysis treatment and hemodynamic response 
Dialysis treatment and laboratory data are shown in Table 2. Of note, HD and HDF 
resulted in comparable patient cooling (-1°C). There were no significant differences 
between UFV or other dialysis treatment or laboratory parameters between study 
arms, except for a larger fall in troponin T (cTnT) following HDF.  
BP was generally well maintained, with no significant differences between modalities 
at any time point (Figure 1A and Table 2). Five patients in each arm had a fall of >20% 
from baseline in at least one systolic BP (SBP) measurement, with an average 
maximum SBP fall of 18.110mmHg during HD and 19.511mmHg during HDF 
(p=0.70); there was only one episode of symptomatic hypotension.  
Heart rate (HR) did not change significantly throughout either dialysis treatment 
(Figure 1C) and no arrhythmias were observed. Stroke volume index (SVI) and cardiac 
index (CI) were independently assessed using PC-MRI and cine MR data. The two 
methods gave tightly correlated results (r=0.61, p<0.001 for SVI; r=0.49, p<0.001 for 
CI), thus for primary analysis PC-MRI measures are presented. Cine MR data are 
provided as Supplementary Material including end diastolic (EDV) and end systolic 
volumes (ESV). SVI and CI both progressively decreased during treatment with lowest 
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values observed at 230min (Figure 1B). No significant differences were found between 
modalities. For HD, baseline CI was 3.6±0.2L/min/m2 versus 2.6±0.2L/min/m2 at 
230min (p=0.001), compared with 3.3±0.2 L/min/m2 and 2.5±0.2L/min/m2 (p=0.001) 
for HDF. A reduction was also seen in IVC flow, but no significant differences were 
found between modalities (Figure 1C).  Cardiac output and systemic vascular 
resistance (SVR) data are provided in the Supplementary Material, together with 
individual patient data showing changes in key parameters for HD and HDF. 
 
Global and segmental ventricular function 
Significant reductions were seen in global circumferential and global longitudinal 
strain during HD and HDF (Figure 2A). During HD, global systolic contractile function 
deteriorated significantly, with longitudinal strain changing from -7.7±0.9% at baseline 
to -4.5±0.8% at 160min (p=0.002) compared with -8.6±0.8% (baseline) and  -4.7±1.0% 
(160min) for HDF (p=0.04). There were no significant differences between HD and 
HDF. Changes were seen as early as 70min into dialysis treatment, with partial or 
complete recovery in the post-dialysis period.   
Regional circumferential and longitudinal strain were each assessed in six LV 
segments, with eight patients demonstrating two or more dysfunctional segments 
during dialysis (>20% reduction in strain from baseline, Figure 2B). Mirroring changes 
in global strain, dysfunctional segments were detected at 70min, with the highest 
number of affected segments at 160min and 250min. There was no difference in 
number of dysfunctional segments between HD and HDF at any time point during 
dialysis. 30min after the end of dialysis, strain returned to baseline in some but not all 
affected segments. There were fewer persistently dysfunctional segments assessed in 
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the long axis view after HD compared to HDF (2.30.4 vs. 3.40.5 respectively, 
p=0.0007). There were no significant differences in fibrosis or myocardial water 
content (as assessed by myocardial T1 signal) at baseline, or during dialysis 
(Supplementary material, Figure 2). 
 
Myocardial perfusion and coronary artery flow 
Whilst there was no clear change in mean myocardial perfusion during dialysis, group-
averaged values masked significant individual variation. Myocardial perfusion fell 
from baseline in seven patients (three 50%) during HD compared with five patients 
(four 50%) during HDF (Chi-squared between modalities p=0.36). For HD, baseline 
perfusion was 3.3±1.7ml/g/min versus an intra-dialytic nadir of 1.9±1.4ml/g/min, 
p=0.05; for HDF, baseline perfusion was 3.4±1.5ml/g/min versus a nadir of 
2.0±1.3ml/g/min, p=0.019. Nadir perfusion values did not differ between HD and HDF 
(Figure 3). Due to the limited spatial coverage of ASL imaging it was not possible to 
formally match myocardial perfusion values to strain on a segmental basis. However, 
78% of patients who had more than two short axis dysfunctional LV segments during 
dialysis (same LV slice in which perfusion was measured) had a >20% fall in myocardial 
perfusion. During HD, four patients demonstrated an early (55min) fall in perfusion 
and three other patients evidenced a later fall (145 or 235min), compared with three 
early decreases and two later decreases during HDF. A significant correlation was 
found between percentage decrease in perfusion from baseline to 70min and number 
of stunned segments for HD, but not for HDF. At baseline, there was no significant 
difference in right coronary artery flow between modalities (mean flux index 1.4 ± 
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0.3L/min/m2, p=0.25). Coronary artery flow did not significantly change during dialysis 
and there was no effect of treatment modality. 
 
Factors associated with changes in cardiac function during dialysis 
The number of dysfunctional long axis segments during dialysis was strongly 
associated with UFV (HD r=0.70, p=0.017; HDF r=0.59, p=0.046), Figure 4A(i). In the 
short axis, a similar association was found for HDF (r=0.66, p=0.026) but not for HD 
(r=0.16, p=0.344), although fewer stunned segments were identified in this view. 
Reductions in SVI and CI during dialysis were both associated with increased UFV 
(Figure 4A(ii)and (iii)). We also observed a trend towards greater UFV in those patients 
with a 20% fall in myocardial perfusion (0.91±0.7L versus 1.5±0.5L, p=0.06). No 
significant correlations were found between UFV and ejection fraction, heart rate or 
IVC flow (as an indicator of venous return).   
In addition, reductions in SVI and CI were associated with the number of dysfunctional 
segments during dialysis (Figure 4B(i) and (ii)). An association between BP and newly 
dysfunctional segments was also seen, with minimum SBP during dialysis correlating 
strongly with number of dysfunctional segments for HD (r=-0.8, p = 0.004) (Figure 
4B(iii)), although not for HDF.   
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Discussion 
 
We have, for the first time, used intra-dialytic MRI to provide a comprehensive 
assessment of the short-term cardiac response to dialysis treatment. Using this 
approach we observed significant intradialytic decreases in cardiac output, myocardial 
contractility and myocardial perfusion but did not observe any differences between 
the short-term cardiac effects of HDF and conventional high-flux HD in the presence 
of cooling.  
The observed haemodynamic responses were in keeping with previous descriptions 
[19, 20]. However, using MRI we have been able to accurately and directly measure 
cardiac output during dialysis for the first time. We observed a substantial decline in 
CI and SVI that reached a nadir at 230min, with only partial recovery post-dialysis. 
Heart rate remained relatively fixed indicating a failure to respond appropriately to 
haemodynamic stress, a finding that is well described [21]. Corresponding reductions 
in IVC flow and EDV suggest that changes in SVI and CI were at least partly related to 
reductions in intravascular volume. However, the negative effects of dialysis on 
ventricular contractility also appeared important, with correlations between change 
in CI and number of newly dysfunctional segments.  
Ventricular contractile performance was assessed using LV strain, with longitudinal 
strain being the most sensitive measure, as the sub-endocardial distribution of 
longitudinal fibres renders them particularly prone to hypoperfusion [22]. We 
observed reductions in both longitudinal and circumferential global strain during 
dialysis, although longitudinal changes were most notable. These global reductions 
were associated with regional/segmental dysfunction. Regional assessment of 
myocardial contractility in tandem with perfusion allowed us to study the 
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development of myocardial stunning more precisely, demonstrating co-existing 
reductions in contractile function and perfusion and only partial recovery post-
dialysis. The pattern of injury, and peak of the effect, was in keeping with 
echocardiography-based studies performed by our group and others [6, 23]. We 
observed myocardial stunning as early as 70min from the start of treatment, 
consistent with early changes in myocardial perfusion described in PET studies [9]. 
This implies that whilst UFV remains a key driver of myocardial stunning, additional 
processes also contribute to regional cardiac injury. That dialysis-induced stunning 
occurs even within modest changes of BP and volume status suggests that there is no 
threshold of risk that can be determined from current clinical based approaches to 
assessment.  
Myocardial perfusion was measured in only a single short-axis slice, due to current 
limitations of the arterial spin labelling scheme used. We observed wide inter- and 
intra-individual variation in myocardial perfusion, a feature not evident in previous 
studies of healthy controls. However, nadir values during dialysis did decline 
significantly during HD and HDF, consistent with previous cardiac PET based studies 
[9, 10]. Whilst coronary artery flow data should be regarded as preliminary, the lack 
of change during dialysis suggests that the observed decrease in myocardial perfusion 
was not due to reduced flow in the main coronary arteries. This strengthens the 
hypothesis that changes in microcirculatory blood flow are the dominant factor 
contributing to tissue ischaemia during dialysis [2].  
Despite randomized controlled trials exploring long-term clinical effects and the 
results of our short-term study, it remains unclear why HDF may have cardio-
protective effects. The Turkish HDF and CONTRAST studies found no difference in 
 11 
mortality or cardiovascular events [15, 16] whereas the ESHOL study reported a large 
(30%) reduction in all-cause mortality [17]. This evidence base is further complicated 
by the divergent results of four meta-analyses, all of which showed reductions in IDH 
with HDF but only one suggested improved patient outcomes [11-14]. A more recent 
pooled individual participant data analysis suggested a survival benefit with HDF, 
particularly with higher convection volumes [18]. Although we observed no significant 
differences between HD and HDF in any of the short-term effects studied, it remains 
possible that HDF may be associated with improved intradialytic stability in more frail 
patient groups with higher UFV. It should be noted that we selected relatively healthy 
patients for this first intra-dialytic MRI study, with well-preserved ejection fraction 
(although baseline strain values were reduced as compared to normal values), 
relatively stable intra-dialytic BP and low UFV. The matched fall in body temperature 
that occurred during study sessions may also be relevant, as dialysate cooling 
improves intradialytic haemodynamic stability and provides short and long-term 
cardio-protection [24, 25]. Previous studies have demonstrated equivalent incidence 
of IDH between HD and convective techniques after controlling for thermal factors 
[26]. It remains possible that HDF may be associated with improved intradialytic 
stability in the long-term related to the cooling effect of large convective replacement 
volumes. HDF does provide superior solute removal over a wide molecular weight 
range as compared to conventional HD, explaining the observed greater clearance of 
cTnT during HDF.  There may be additional, unknown short-term effects associated 
with the removal of other factors, such as cardiotonic steroids, which have been 
experimentally associated with the development of uremic cardiomyopathy [27] but 
this remains speculative. 
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T1 relaxation measures can provide an indication of the degree of myocardial fibrosis 
as collagen becomes associated with a supersaturated hydrogel and increases the 
water based signal [28], whilst a change in T1 during dialysis would indicate altered 
myocardial water content. Our cohort had relatively normal baseline T1 values 
suggesting a low level of cardiac fibrosis, and a lack of change in T1 during dialysis 
indicates no change in myocardial water/oedema due to UFV or osmolality changes. 
However, further study of these measures may provide additional insights across a 
wider patient demographic.  
 The application of advanced cardiac MRI during dialysis is a major step forward 
towards understanding the pathophysiology of elevated cardiovascular mortality in 
dialysis patients. We have confirmed the development of myocardial stunning during 
optimal dialysis schedules and shown that cardiac MRI now provides an integrated 
tool for the discovery of new dialysis-based therapeutic targets, refinement of 
candidate interventions and ascertainment of robust biological plausibility, prior to 
large-scale studies to improve intradialytic haemodynamic stability directed at ‘hard’ 
clinical endpoints. In the setting of this study of stable cooled patients, HDF and high-
flux HD were associated with similar short-term intradialytic cardiac effects. 
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Concise Methods 
Subject Demographics and clinical data  
Patients were recruited to the study from the renal unit at Royal Derby Hospital 
(ClinicalTrials.gov:NCT02494843). One of the investigators (AM) was responsible for 
enrolling participants. Ethical approval was grant by Derbyshire Research Ethics 
committee and all patients gave written informed consent. All patients had received 
thrice weekly HD for more than six months and had a mature arteriovenous fistula. 
Patients were excluded if they fulfilled the criteria for New York Heart Association 
Class 4 cardiac failure.  
 
Study design 
This was an open-label randomised crossover pilot trial (Figure 5A). Participants were 
randomised 1:1 to HD or HDF for two weeks using a computer generated 
randomisation sequence (Prism, GraphPad, San Diego CA), after which they 
underwent multi-parametric cardiac MRI scans before, during and after a single 
dialysis treatment (Figure 5B). Clinical parameters, dialysis treatment details and 
laboratory tests were obtained before and after dialysis. Thereafter, participants 
switched to the other modality for a further two weeks before attending for a second 
MRI study day. During the two-week run-in phases, dry weight was assessed as per 
standard clinical practice, and dialysis was performed with the same equipment as 
used on study days: Fresenius 5008 monitors, high flux polysulfone dialysers (FX800, 
Fresenius Medical Care, Germany), bicarbonate buffer, dialysate temperature 370C. 
For HDF, a minimum of 20L replacement fluid per treatment was targeted. 
Anticoagulation was achieved using unfractionated heparin and dialysate composition 
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was sodium 137mmol/L, potassium 2.0mmol/L, calcium 1.5mmol/L, magnesium 
0.5mmol/L, glucose 1.0g/L. 
 
Cardiac imaging 
Cardiac MRI data were collected on a 3T Philips Achieva MR scanner (Philips Medical 
Systems, Best, NL) using MultiTransmit and a 16-channel TorsoXL receive coil. There 
were a number of considerations to allow dialysis to be performed in the MR 
scanner, as described in the Appendix. Cardiac MRI data were collected at five time 
points (Figure 5B) and comprised multiple measures of cardiac structure and 
function, alongside VCG measures of patient heart rate, in a 50min scan session. 
MRI measures are summarised below, full technical details are provided in the 
Appendix. 
 
Global cardiac contractile function: Left ventricular function was assessed using VCG-
gated cine MRI to collect images of the LV across the cardiac cycle in the two-chamber 
(2CH) view. Data were analysed using ViewForum software (Philips Medical Systems, 
Best, NL). Cardiac output (CO), stroke volume (SV) and ejection fraction were 
determined. SV and CO measures were corrected for body surface area (BSA), to yield 
stroke volume index (SVI) (L/m2) and cardiac index (CI) (L/min/m2).  
 
Aortic flow and central venous return: Phase contrast (PC) MRI of aortic flow was 
collected to provide a second independent estimate of SVI and CI, while PC-MRI of the 
inferior vena cava (IVC) was used to determine central venous return. PC-MRI data 
were analysed using ViewForum software to provide an estimate of aortic blood 
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velocity (mm/s), cross sectional area (CSA) of the aorta (mm2) and aortic strain (%), 
from which SVI and CVI could be obtained. For the IVC, velocity (mm/s), flux (L/min) 
and CSA (mm2) were calculated, with flux and CSA being BSA corrected.  
 
Segmental cardiac function: Contractility and myocardial strain were assessed using 
SPAMM tagging. Data were collected in a 2CH short axis slice to compute peak systolic 
circumferential strain and in a long axis four-chamber (4CH) slice to measure 
longitudinal strain. Using CIM2D software (Auckland Uni Services), images were 
divided into six segments (short axis: anterior septum, anterior, anterior lateral, 
posterior lateral, inferior and inferior septum; long axis: basal inferior, mid inferior, 
apical inferior, apical anterior, mid anterior and basal anterior). Circumferential and 
longitudinal strain (%) was measured for each segment, and percentage change in 
each segment was assessed during dialysis. A reduction in strain >20% from baseline 
was taken to define segments that became dysfunctional during dialysis [29].  
 
Myocardial fibrosis: Myocardial fibrosis was assessed in a 2CH short axis slice, using a 
modified Look-Locker inversion recovery (MOLLI) T1 mapping scheme [30]. MOLLI data 
were analyzed using dedicated software to form short axis T1 maps (in ms) of the 
myocardium (Matlab version 8.1, The MathWorks, Inc., Natick, MA, USA).  
 
Coronary blood flow: PC-MRI was used to estimate flow in the right coronary artery. 
Using ViewForum software, the cross sectional area (mm2), flux of blood through the 
coronary artery (ml/min) and stroke volume (mL), were calculated and BSA corrected.  
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Myocardial perfusion: Myocardial perfusion was assessed in a 2CH short axis slice with 
a MOLLI arterial spin labeling (ASL) technique [31] using a flow alternating inversion 
recovery (FAIR) scheme. Myocardial perfusion data were quantified in units of 
ml/g/min (Matlab version 8.1, The MathWorks, Inc., Natick, MA, USA). 
 
Statistical Analyses 
Statistical analysis was performed using SPSS v22. Results are expressed as 
mean±standard error (SE) and median (interquartile range, IQR) for parametric and 
non-parametric data respectively. Paired T-test (or non-parametric equivalent) or 
repeated measures ANOVA were used to compare variables over two or more time-
points and between modalities. Correlations were performed with Pearson tests. The 
null hypothesis was accepted for p-values 0.05.  
As cardiac ASL has never been assessed previously in the context of CKD5, and because 
of the technical considerations of performing intradialytic MRI, the sample size was 
selected pragmatically based on published norms of cardiac stunning during dialysis 
in human studies [25] and animal studies using cardiac MRI [32]. However, using data 
from previous echocardiography-based studies and assuming a mean±SD of 4.81.3 
new regional wall motion abnormalities (RWMAs) per patient with standard dialysis 
[33] [33], 11 patients per group would be required to have a 90% chance of detecting 
a decrease in new RWMAs from 4.8 in standard dialysis to 3.0 in the HDF group, 
significant at the 5% level. Such a reduction would be clinically significant and in 
keeping with other dialysis based interventions shown previously to reduce dialysis-
induced myocardial stunning [23, 33].  
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 Figure Legends 
Figure 1: Blood pressure and cardiovascular responses pre-, during, and post- dialysis 
for HD and HDF treatments. A) Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) data, B) SVI and CI measured using PC-MRI of aortic flow, showing a 
significant decrease during dialysis reaching a nadir after 230min and partial recovery 
at 50min post-dialysis, C) IVC flux showing a decrease during dialysis and recovery 
following treatment. Heart rate which did not change significantly throughout either 
dialysis treatment, but at 240 min was significantly different (*) between HD and HDF 
(p < 0.05). 
 
Figure 2: A) (i) Whole wall short axis circumferential strain and (ii) whole wall 
longitudinal strain. Strain is seen to decrease (i.e. become less negative indicating less 
strain) during dialysis and subsequently return to baseline 70min post dialysis. B) (i) 
Number of dysfunctional segments in the short axis and (ii) number of dysfunctional 
segments in the long axis at time points during HD or HDF. Dysfunctional segments 
(>20% reduction in strain from baseline) are evident from 70min and then decrease 
but do not return to baseline following treatment. There were no differences in 
number of dysfunctional segments between HD and HDF at any time point (Repeated 
measures ANOVA across the five time points and between treatments). However on 
performing a paired t-test, a significant difference was seen between the two 
treatments at 70 min post (p = 0.01).  
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Figure 3: Baseline perfusion and nadir perfusion during dialysis for both HD and HDF. 
A significant decrease in perfusion is seen for both treatment modalities. 
 
Figure 4: A) (i) A positive correlation between number of dysfunctional LV segments 
in the long axis and UFV for HD (r = 0.70, p = 0.017) and HDF (r = 0.59, p = 0.046). (ii) 
A negative correlation between change in SVI during dialysis and UFV (r = -0.813, p= 
0.001 for HD; r = -0.838, p = 0.001 for HDF). (iii) A negative correlation between change 
in CI during dialysis and UFV (r = -0.831, p= 0.000 for HD and r = -0.845, p = 0.001 for 
HDF). B)  (i) A negative correlation between change in SVI during dialysis and number 
of dysfunctional LV segments (r = -0.720, p= 0.014 for HD and r = -0.698, p = 0.018 for 
HDF). (ii) A negative correlation between change in CI during dialysis and number of 
dysfunctional LV segments (r = -0.502, p> 0.1 for HD and r = -0.716, p = 0.015 for HDF). 
(iii) A negative correlation between minimum SBP and number of dysfunctional LV 
segments was found for HD (r = -0.8, p = 0.004) but not HDF. 
 
Figure 5: A) Crossover randomised controlled trial design. Patients were randomised 
to HD or HDF for two weeks, after which they attended a cardiac MRI scan which was 
performed before, during, and after a dialysis session. Thereafter, participants 
switched to the other treatment for a further 2 weeks, after which cardiac MRI 
assessment was again performed. B) Details of cardiac MR scan sessions, with the 
timing of the acquisition of each of the multiple MRI measures of cardiac structure and 
function that were collected in each 50min MR scan session. 
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Tables 
Table 1: Patient demographic data 
 
Ethnicity: Caucasian (n) 9        (75%) 
Male (n) 10      (83.3%) 
Age (years) 53 ± 12 
Dialysis vintage (months) 56 ± 6 
Fistula flow rate, Qa  (ml/min) 1051 ± 60 
BMI 24.7   (21.7 to 30) 
Dry Weight (kg)  79      (56.5 to 92.8) 
Primary Renal Diagnosis 
Unknown 
Polycystic kidneys 
Diabetic nephropathy 
Other  
  
3     (25%) 
3     (25%) 
2     (16.7%) 
4     (33.3%)) 
Diabetes mellitus 4     (33.3%) 
Current smoker 2 (16.7%) 
Residual renal function (creatinine clearance, ml/min) 1 (0-4) 
NYHA status 
No Heart Failure  
Heart Failure NYHA Class1  
 
11 (91.7%) 
 1 (8.3%) 
Charlson Comorbidity Index (Age Adjusted)  4 (3 to 5) 
Medications 
ACEi/ARB 
Beta-blockers 
2 or more anti-hypertensive agents 
 
5 (41%) 
4 (33.3%) 
4 (33.3%) 
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Table 2: Dialysis treatment data and laboratory parameters for haemodialysis (HD) and 
haemodiafiltration (HDF) study sessions. IDWG = interdialytic weight gain, IDH = 
intradialytic hypotension, UF = ultrafiltration, SBP = systolic blood pressure, DBP = 
diastolic blood pressure, URR = urea reduction ratio. Data presented as mean ± 
standard error or median (interquartile range). 
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 HD HDF p 
DIALYSIS TREATMENT DATA  
IDWG (% body weight) 2.13% (0.90 to 3.6)  2.0% (1.4 to 3.47) 0.38 
Blood flow rate (ml/min) 365 (350 to 387)  365 (352 to 389)  0.82 
Substitution volume (L) n/a 23.0  2.5 
 
UF rate (ml/kg/hr) 3.8  2.9 4.4  2.5 
0.29 
UF volume (L)  1.1  0.7 1.3  0.6 
0.41 
SBP (mmHg) 
Pre     150.2  23.40  
During 140.9  6 
Post   144.3  18.20  
Pre    150.3  22.78 
During 142.2  6 
Post  140.7  21.26 
0.43 
0.46 
0.25 
DBP (mmHg) 
Pre     80.58  12.95 
During 78.8  12 
Post   80.25  14.69 
Pre     75.92  13.05 
During 77.0  12 
Post   80.00  12.21 
0.93 
0.28 
0.21 
Tympanic temperature pre- to 
post-dialysis (oC) 
 
-1.0  0.4 
 
-1.0  0.4 
 
0.98 
Number of IDH episodes 0  1  
 
BLOOD SAMPLE DATA  
 
Haemoglobin (g/L) 119.5  7 120.8  3 
0.60 
URR (%) 74.6  9 75.6  9 
0.28 
Bicarbonate (mmol/L) 24 (21 to 25) 23.5    (22 to 24.7) 
0.83 
Adjusted Calcium (mmol/L) 2.38  0.13 2.48  0.11 
0.09 
Phosphate (mmol/L) 1.43  0.38 1.47  0.31 
0.69 
PTH (ng/L) 191.0 (146.8 to 49.3) 200 (139 to 307.8) 
0.52 
Magnesium (mmol/L) 0.98  0.14 1.03  0.15 
0.10 
nT-proBNP (ng/L) 2145 (1102 to 3379) 1512 (1026 to 2261) 
0.052 
Pre dialysis cTnT (ng/L) 64.7  70 62.4  58 
0.65 
Post dialysis cTnT (ng/L) 53.8  57 37.3  32 
0.043 
Pre-dialysis sodium (mmol/L) 140.5  0.7  140.6  0.5  
0.68 
Post-dialysis sodium (mmol/L) 139.0  0.5   138.8  0.4 
0.74 
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